GlaxoSmithKline-backed Atreca has now raised $91m in total and will use the series B proceeds to advance a pipeline of therapeutics based on human immune responses.
Atreca, a US-based, immune system-focused drug developer that counts pharmaceutical firm GlaxoSmithKline (GSK) as an investor, closed a $35m series B round today.
Investment management firm Wellington Management Company co-led the round with an undisclosed US-based, healthcare-focused fund, most likely the same one that led Atreca’s $56m series A round in late 2015.
The series B round also featured hedge fund sponsor Cormorant Asset Management and unnamed new and existing investors. GSK, Mission Bay Capital and Bill and Melinda…
